Since late 2019, VytlOne has supported the 340B programs of 33 health systems and 38 health centers. Altogether, we’ve generated nearly $1 billion in pharmacy-related savings for our clients. We analyze 340B program-savings potential for dozens of prospective clients every year. And not once have we ever served, or encountered, a health system capable of … Read More
Download Our Free Compliance Checklist PDF 340B health systems have been under increasing scrutiny and regulatory oversight in recent years. The Health Resources and Services Administration (HRSA) has indicated that it plans to increase the number and complexity of 340B program audits it conducts. Here’s how your health system can prepare every aspect of … Read More
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More
Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More
Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of VytlOne’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More
The automated approach to optimizing 340B savings & patient care while overcoming manufacturer restrictions NOTE: The purpose of this article is to highlight features and functionality any 340B platform needs to optimize a health system’s 340B savings and revenue. That said, we determined that the easiest way to report those features was to describe the … Read More
Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More
The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More
A covered entity’s guide to selecting TPAs for its 340B program TPAs play a critical role in any covered entity’s 340B program. It’s their job to match contract pharmacies’ prescription claims with patient data provided by the health systems they serve, to determine 340B eligibility — and generate entity savings. Without those matches, no prescriptions … Read More
Two DOPs Deal With Operations, The 340B Program, And Drug Manufacturers’ Restrictions VytlOne recently organized an introductory Zoom meeting between the DOPs of two health systems we serve. Southwest Mississippi Regional Medical Center’s (SMRMC) Tiffany Poole earned her Doctorate of Pharmacy degree from the University of Mississippi in 2006. A VytlOne pharmacist since 2018, she … Read More
